Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease
Frontiers in Pharmacology · 23.01.2025 · 16
DOI: 10.3389/fphar.2025.1505117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.01.2025. Verfasst von Wei Xuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreaticobiliary Surgery, China-Japan Union Hospital, Jilin University, Changchun, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to induce liver senescence and ferroptosis, which are hot topics in the research of MASLD. Recent studies have shown that Hippo–YAP1/TAZ pathway is involved in the regulations of metabolism disorders, senescence, ferroptosis, inflammation, and fibrosis in MASLD, but their complex connections and contrast roles are also reported. In addition, therapeutics based on the Hippo–YAP1/TAZ pathway hold promising for MASLD treatment. In this review, we highlight the regulation and molecular mechanism of the Hippo–YAP1/TAZ pathway in MASLD and summarize potential therapeutic strategies for MASLD by regulating Hippo–YAP1/TAZ pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatopancreaticobiliary Surgery, China-Japan Union Hospital, Jilin University, Changchun, China.
- Department of Clinical Laboratory, Second Hospital of Jilin University, Changchun, China.
- Department of Endodontics, Hospital of Stomatology, Jilin University, Changchun, China.
Zitieren
APA
Xuan, W., Song, D., Hou, J., & Meng, X. (2025). Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1505117
Vancouver
Xuan W, Song D, Hou J, Meng X. Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1505117
BibTeX
@article{Xuan2025,
author = {Xuan, Wei and Song, Dandan and Hou, Jianghua and Meng, Xiuping},
title = {Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1505117}
}
EUVIMED